BIRKMANN; Alexander

Patent Applications and Registrations

Patent applications and USPTO patent grants for BIRKMANN; Alexander.The latest application filed is for "maleate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridiny- l)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof".

Company Profile

4.8.11

BIRKMANN; Alexander - Wuppertal DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Maleate Salt Of The Free Base Of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridiny- L)-phenyl]-acetamide, Pharmaceutical Formulations, Methods Of Manufacture And Uses Thereof App 20220152009 - BACHHAV; Yogeshwar ; et al.	2022-05-19
Maleate salt of the free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridiny- l)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof for the treatment of herpes viruses Grant 11,266,636 - Bachhav , et al. March 8, 2	2022-03-08
Intravaginally applicable devices comprising antiviral compounds Grant 11,213,516 - Bachhav , et al. January 4, 2	2022-01-04
N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl- )-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof App 20210269429 - BACHHAV; Yogeshwar ; et al.	2021-09-02
N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl- )-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof Grant 11,021,474 - Bachhav , et al. June 1, 2	2021-06-01
A Maleate Salt Of The Free Base Of N-[5-(aminosulfonyl)-4-methyl-1.3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridiny- L)-phenyl]-acetamide, Pharmaceutical Formulations, Methods Of Manufacture And Uses Thereof For The Treatment Of Herpes Viruses App 20200289485 - BACHHAV; Yogeshwar ; et al.	2020-09-17
Intravaginally Applicable Devices Comprising Antiviral Compounds App 20200121664 - BACHHAV; Yogeshwar ; et al.	2020-04-23
N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl- )-phenyl]-acetamide free base hemihydrate, methods o App 20200123145 - BACHHAV; Yogeshwar ; et al.	2020-04-23
Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2[4-(2-pyridinyl- )phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations Grant 10,137,117 - Schwab , et al. November 27, 2	2018-11-27
Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridiny- l)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations Grant 9,889,124 - Schwab , et al. February 13, 2	2018-02-13
Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n- Methyl-2-[4-(2-pyridinyl)phenyl]acetamide Mono Mesylate Monohydrate Having A Specific Particle Size Distribution Range And A Specific Surface Area Range For Use In Pharmaceutical Formulations App 20170348297 - SCHWAB; Wilfried ; et al.	2017-12-07
Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridiny- l)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations Grant 9,592,225 - Schwab , et al. March 14, 2	2017-03-14
N-[5-(Aminosulfony1)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl- )phenyl]acetamide mesylate monohydrate Grant 9,340,535 - Schwab , et al. May 17, 2	2016-05-17
Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridiny- L)phenyl]acetamide Mono Mesylate Monohydrate Having A Specific Particle Size Distribution Range And A Specific Surface Area Range For Use In Pharmaceutical Formulations App 20160008341 - SCHWAB; Wilfried ; et al.	2016-01-14
Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridiny- L)phenyl]acetamide Mono Mesylate Monohydrate Having A Specific Particle Size Distribution Range And A Specific Surface Area Range For Use In Pharmaceutical Formulations App 20150366849 - SCHWAB; Wilfried ; et al.	2015-12-24
Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridiny- l)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations Grant 9,119,786 - Schwab , et al. September 1, 2	2015-09-01
N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl- )phenyl]acetamide mesylate monohydrate App 20140221433 - Schwab; Wilfried ; et al.	2014-08-07
Crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridiny- L)phenyl]acetamide Mono Mesylate Monohydrate Having A Specific Particle Size Distribution Range And A Specific Surface Area Range For Use In Pharmaceutical Formulations App 20140065224 - SCHWAB; Wilfried ; et al.	2014-03-06
Biphenyl Substituted Spirotetronic Acids And Their Use For The Treatment Of Retroviral Diseases App 20100022527 - HEIMBACH; Dirk ; et al.	2010-01-28

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.